Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline

Tatsuo Ohira, Yuichiro Ohe, Yuji Heike, Eckhard R. Podack, Kristin J. Olsen, Kazuto Nishio, Makoto Nishio, Yuki Miyahara, Yasunori Funayama, Hayato Ogasawara, Hitoshi Arioka, Harubumi Kato, Nagahiro Saijo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Gene therapy with cytokine cDNA will provide a new tool for cancer treatment. We have already reported that immunization with interleukin-2 (IL2) cDNA transfected Lewis lung carcinoma (LLC) cells induced anti-tumor immunity, which, however, was not strong enough to eradicate an established tumor. In an attempt to develop more effective gene therapy methods, we have used tumor cells co-transfected with IL-2 and tumor necrosis factor (TNF) cDNAs. These cDNAs were introduced into pBMG-Neo and pcDV-X819 vectors, respectively, and then co-transfected into LLC cells. The co-transfectants were selected by incubating them in a medium containing G418 followed by the limiting dilution method twice to obtain IL2 and TNF cDNA co-transfected LLC (LLC-TNF-IL2) cells. When 5 × 105/ml LLC-TNF-IL2 cells were incubated for 48 h, they secreted 7.56 U/ml TNF and 527.0 U/ml IL2 into the culture supernatant. When C57BL/6 mice were transplanted with 1 × 106 LLC-TNF-IL2 cells, all the tumors were rejected. The growth of transplanted LLC, but not B16F10 melanoma cells, was retarded in mice inoculated with LLC-TNF-IL2 on their contralateral sides, which suggests specific immunity was induced. The immunization effect by the co-transfectant was superior to that of the IL2- and TNF-transfectants alone.

Original languageEnglish
Pages (from-to)269-275
Number of pages7
JournalGene Therapy
Volume1
Issue number4
StatePublished - Dec 1 1994
Externally publishedYes

Fingerprint

Lewis Lung Carcinoma
Genetic Therapy
Interleukin-2
Complementary DNA
Tumor Necrosis Factor-alpha
Neoplasms
Immunity
Immunization
Inbred C57BL Mouse
Melanoma
Cytokines

ASJC Scopus subject areas

  • Genetics

Cite this

Ohira, T., Ohe, Y., Heike, Y., Podack, E. R., Olsen, K. J., Nishio, K., ... Saijo, N. (1994). Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline. Gene Therapy, 1(4), 269-275.

Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline. / Ohira, Tatsuo; Ohe, Yuichiro; Heike, Yuji; Podack, Eckhard R.; Olsen, Kristin J.; Nishio, Kazuto; Nishio, Makoto; Miyahara, Yuki; Funayama, Yasunori; Ogasawara, Hayato; Arioka, Hitoshi; Kato, Harubumi; Saijo, Nagahiro.

In: Gene Therapy, Vol. 1, No. 4, 01.12.1994, p. 269-275.

Research output: Contribution to journalArticle

Ohira, T, Ohe, Y, Heike, Y, Podack, ER, Olsen, KJ, Nishio, K, Nishio, M, Miyahara, Y, Funayama, Y, Ogasawara, H, Arioka, H, Kato, H & Saijo, N 1994, 'Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline', Gene Therapy, vol. 1, no. 4, pp. 269-275.
Ohira T, Ohe Y, Heike Y, Podack ER, Olsen KJ, Nishio K et al. Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline. Gene Therapy. 1994 Dec 1;1(4):269-275.
Ohira, Tatsuo ; Ohe, Yuichiro ; Heike, Yuji ; Podack, Eckhard R. ; Olsen, Kristin J. ; Nishio, Kazuto ; Nishio, Makoto ; Miyahara, Yuki ; Funayama, Yasunori ; Ogasawara, Hayato ; Arioka, Hitoshi ; Kato, Harubumi ; Saijo, Nagahiro. / Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline. In: Gene Therapy. 1994 ; Vol. 1, No. 4. pp. 269-275.
@article{110822afd24c4a949231c826ac730fcf,
title = "Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline",
abstract = "Gene therapy with cytokine cDNA will provide a new tool for cancer treatment. We have already reported that immunization with interleukin-2 (IL2) cDNA transfected Lewis lung carcinoma (LLC) cells induced anti-tumor immunity, which, however, was not strong enough to eradicate an established tumor. In an attempt to develop more effective gene therapy methods, we have used tumor cells co-transfected with IL-2 and tumor necrosis factor (TNF) cDNAs. These cDNAs were introduced into pBMG-Neo and pcDV-X819 vectors, respectively, and then co-transfected into LLC cells. The co-transfectants were selected by incubating them in a medium containing G418 followed by the limiting dilution method twice to obtain IL2 and TNF cDNA co-transfected LLC (LLC-TNF-IL2) cells. When 5 × 105/ml LLC-TNF-IL2 cells were incubated for 48 h, they secreted 7.56 U/ml TNF and 527.0 U/ml IL2 into the culture supernatant. When C57BL/6 mice were transplanted with 1 × 106 LLC-TNF-IL2 cells, all the tumors were rejected. The growth of transplanted LLC, but not B16F10 melanoma cells, was retarded in mice inoculated with LLC-TNF-IL2 on their contralateral sides, which suggests specific immunity was induced. The immunization effect by the co-transfectant was superior to that of the IL2- and TNF-transfectants alone.",
author = "Tatsuo Ohira and Yuichiro Ohe and Yuji Heike and Podack, {Eckhard R.} and Olsen, {Kristin J.} and Kazuto Nishio and Makoto Nishio and Yuki Miyahara and Yasunori Funayama and Hayato Ogasawara and Hitoshi Arioka and Harubumi Kato and Nagahiro Saijo",
year = "1994",
month = "12",
day = "1",
language = "English",
volume = "1",
pages = "269--275",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline

AU - Ohira, Tatsuo

AU - Ohe, Yuichiro

AU - Heike, Yuji

AU - Podack, Eckhard R.

AU - Olsen, Kristin J.

AU - Nishio, Kazuto

AU - Nishio, Makoto

AU - Miyahara, Yuki

AU - Funayama, Yasunori

AU - Ogasawara, Hayato

AU - Arioka, Hitoshi

AU - Kato, Harubumi

AU - Saijo, Nagahiro

PY - 1994/12/1

Y1 - 1994/12/1

N2 - Gene therapy with cytokine cDNA will provide a new tool for cancer treatment. We have already reported that immunization with interleukin-2 (IL2) cDNA transfected Lewis lung carcinoma (LLC) cells induced anti-tumor immunity, which, however, was not strong enough to eradicate an established tumor. In an attempt to develop more effective gene therapy methods, we have used tumor cells co-transfected with IL-2 and tumor necrosis factor (TNF) cDNAs. These cDNAs were introduced into pBMG-Neo and pcDV-X819 vectors, respectively, and then co-transfected into LLC cells. The co-transfectants were selected by incubating them in a medium containing G418 followed by the limiting dilution method twice to obtain IL2 and TNF cDNA co-transfected LLC (LLC-TNF-IL2) cells. When 5 × 105/ml LLC-TNF-IL2 cells were incubated for 48 h, they secreted 7.56 U/ml TNF and 527.0 U/ml IL2 into the culture supernatant. When C57BL/6 mice were transplanted with 1 × 106 LLC-TNF-IL2 cells, all the tumors were rejected. The growth of transplanted LLC, but not B16F10 melanoma cells, was retarded in mice inoculated with LLC-TNF-IL2 on their contralateral sides, which suggests specific immunity was induced. The immunization effect by the co-transfectant was superior to that of the IL2- and TNF-transfectants alone.

AB - Gene therapy with cytokine cDNA will provide a new tool for cancer treatment. We have already reported that immunization with interleukin-2 (IL2) cDNA transfected Lewis lung carcinoma (LLC) cells induced anti-tumor immunity, which, however, was not strong enough to eradicate an established tumor. In an attempt to develop more effective gene therapy methods, we have used tumor cells co-transfected with IL-2 and tumor necrosis factor (TNF) cDNAs. These cDNAs were introduced into pBMG-Neo and pcDV-X819 vectors, respectively, and then co-transfected into LLC cells. The co-transfectants were selected by incubating them in a medium containing G418 followed by the limiting dilution method twice to obtain IL2 and TNF cDNA co-transfected LLC (LLC-TNF-IL2) cells. When 5 × 105/ml LLC-TNF-IL2 cells were incubated for 48 h, they secreted 7.56 U/ml TNF and 527.0 U/ml IL2 into the culture supernatant. When C57BL/6 mice were transplanted with 1 × 106 LLC-TNF-IL2 cells, all the tumors were rejected. The growth of transplanted LLC, but not B16F10 melanoma cells, was retarded in mice inoculated with LLC-TNF-IL2 on their contralateral sides, which suggests specific immunity was induced. The immunization effect by the co-transfectant was superior to that of the IL2- and TNF-transfectants alone.

UR - http://www.scopus.com/inward/record.url?scp=0028464345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028464345&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 269

EP - 275

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 4

ER -